Item 8.01 Other Events.

On October 7, 2021, Ultragenyx Pharmaceutical Inc. (the "Company") and GeneTx Biotherapeutics LLC ("GeneTx") issued a press release (the "Press Release") announcing that the first patient has been dosed in the Phase 1/2 study of GTX-102, an investigational treatment for Angelman syndrome, with three other patients enrolled and scheduled to begin dosing. A copy of the Press Release is filed as Exhibit 99.1

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit No. Description
99.1          Press Release, dated October 7, 2021.
104         The cover page from the Company's Current Report on Form 8-K dated
            October 7, 2021 formatted in Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses